-
Caliper Life Sciences - Aggressive Growth
Tuesday, January 25, 2011 - 1:00am | 430Caliper Life Sciences (CALP) recently announced preliminary financial results that breathed some life into the stock. Estimates are moving higher as a result. CALP currently has a Zacks #1 Rank (Strong Buy) and continues to expand into new markets. Company Description Caliper Life Sciences...
-
Charles River Laboratories Adds Two New Board Members
Monday, January 24, 2011 - 5:19pm | 42Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointments of Robert J. Bertolini and Richard F. Wallman to the Company's Board of Directors and thanked two exiting directors for their outstanding service.
-
AstraZeneca Responds to FDA Letter - Analyst Blog
Monday, January 24, 2011 - 5:01pm | 479AstraZeneca (AZN) recently submitted a response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) for Brilinta (ticagrelor). In its response, the company has provided additional analyses of the Study of Platelet Inhibition and Patient Outcomes (PLATO) as...
-
AstraZeneca Responds to FDA Letter - Analyst Blog
Monday, January 24, 2011 - 4:40pm | 479AstraZeneca (AZN) recently submitted a response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) for Brilinta (ticagrelor). In its response, the company has provided additional analyses of the Study of Platelet Inhibition and Patient Outcomes (PLATO) as...
-
Meridian Misses on Lower Flu Sales - Analyst Blog
Monday, January 24, 2011 - 12:31pm | 779Diagnostic test kit maker Meridian Bioscience (VIVO) reported disappointing first quarter fiscal 2011 (ended December 31) results with earnings of 15 cents per share trailing the Zacks Consensus Estimate of 19 cents and the year-ago earnings of 22 cents per share. Profit plummeted 32% year over...
-
Meridian Misses on Lower Flu Sales - Analyst Blog
Monday, January 24, 2011 - 12:15pm | 779Diagnostic test kit maker Meridian Bioscience (VIVO) reported disappointing first quarter fiscal 2011 (ended December 31) results with earnings of 15 cents per share trailing the Zacks Consensus Estimate of 19 cents and the year-ago earnings of 22 cents per share. Profit plummeted 32% year over...
-
BioDelivery Sciences Refutes Patent Claim by MonoSol Rx
Friday, January 21, 2011 - 10:02am | 179BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today responded to a process patent infringement lawsuit filed and recently served against the Company and certain co-defendants by MonoSol Rx, LLC. “After careful examination, we refute MonoSol's assertion of patent infringement, which...
-
Commonwealth Biotechnologies, Inc. Files Chapter 11
Friday, January 21, 2011 - 10:01am | 54Commonwealth Biotechnologies, Inc. (CBTE) announced today that it has filed for reorganization under Chapter 11 bankruptcy in order to complete its planned divestment of assets and subsequent identification of a merger partner in an orderly and efficient way. The process could take up to 12-18...
-
PPDI Guides Above Expectations - Analyst Blog
Thursday, January 20, 2011 - 11:31am | 545Pharmaceutical Product Development Inc. (PPDI) recently provided financial guidance for 2011. The company also plans to resume its share repurchase program announced earlier. Pharmaceutical Product Development expects revenue to range between $1.48 billion and $1.58 billion in 2011,...
-
Company News for January 20, 2011 - Corporate Summary
Thursday, January 20, 2011 - 11:01am | 619• Share prices of tech major IBM (NYSE:IBM) rose by 3.35% after the company posted excellent earnings figure on Tuesday night • Adtran Inc (NASDAQ:ADTN) increased 6.56% to end at $42.25 after the company posted an increased sales figures for the fourth quarter that came in above expectations • ...
-
MannKind in Jeopardy - Analyst Blog
Thursday, January 20, 2011 - 11:01am | 917MannKind Corp. (MNKD) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for its new drug application (NDA) for type I and type II diabetes treatment Afrezza. MannKind's share price plummeted 44% in after hours trading,...
-
PPDI Guides Above Expectations - Analyst Blog
Thursday, January 20, 2011 - 11:00am | 545Pharmaceutical Product Development Inc. (PPDI) recently provided financial guidance for 2011. The company also plans to resume its share repurchase program announced earlier. Pharmaceutical Product Development expects revenue to range between $1.48 billion and $1.58 billion in 2011,...
-
MannKind in Jeopardy - Analyst Blog
Thursday, January 20, 2011 - 10:45am | 924MannKind Corp. (MNKD) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for its new drug application (NDA) for type I and type II diabetes treatment Afrezza. MannKind's share price plummeted 44% in after hours trading,...
-
Jefferies Raises PT on Pharm. Product Devel. (PPDI)
Thursday, January 20, 2011 - 10:34am | 120Jefferies is out with its report today on Pharm. Product Devel. (NASDAQ: PPDI) raising its PT on PPDI from $29 to $32. In a note to clients, Jefferies writes, "PPDI issued 2011 guidance above analyst expectations. It expects 2011 revenue of $1.48-1.58B and EPS at $1.53-1.69. Our revenue estimate of...
-
Company News for January 20, 2011 - Corporate Summary
Thursday, January 20, 2011 - 10:15am | 619• Share prices of tech major IBM (NYSE:IBM) rose by 3.35% after the company posted excellent earnings figure on Tuesday night • Adtran Inc (NASDAQ:ADTN) increased 6.56% to end at $42.25 after the company posted an increased sales figures for the fourth quarter that came in above expectations • ...